• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 20-F filed by Bruush Oral Care Inc.

    2/29/24 4:30:17 PM ET
    $BRSH
    Medical/Dental Instruments
    Health Care
    Get the next $BRSH alert in real time by email
    NT 20-F 1 formnt20-f.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    (Check One): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR
       
      For Period Ended: October 31, 2023
      ☐ Transition Report on Form 10-K
      ☐ Transition Report on Form 20-F
      ☐ Transition Report on Form 11-K
      ☐ Transition Report on Form 10-Q
      ☐ Transition Report on Form N-SAR
       
      For the Transition Period Ended: ________________________

     

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

     

    PART I — REGISTRANT INFORMATION

     

    BRUUSH ORAL CARE INC.

     

    Full name of registrant:

     

     

     

    Former name if applicable:

     

    128 West Hastings Street, Unit 210

     

    Address of principal executive office (Street and number):

     

    Vancouver, British Columbia V6B 1G8

     

    City, state and zip code

     

     

     

     

     

     

    PART II — RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

     

      (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
         
    ☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
         
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III — NARRATIVE

     

    State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    Registrant is unable to file its Form 20-F for the fiscal year ended October 31, 2023 by the prescribed filing date because Registrant requires additional time to review its financial statements to finalize the Form 20-F. Registrant anticipates that it will file the Form 20-F no later than the fifteenth calendar day following the prescribed filing date.

     

    PART IV — OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

      Aneil Manhas   (604)   808-5858
      (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
       
      ☒ Yes ☐ No
       
    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
       
      ☐ Yes ☒ No

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

     

     

    BRUUSH ORAL CARE INC.

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: February 29, 2024 By /s/ Aneil Manhas
        Aneil Manhas
        Chief Executive Officer

     

    INSTRUCTION. The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

     

    ATTENTION

     

    Intentional misstatements or omissions of fact constitute Federal criminal violations. (See 18 U.S.C. 1001).

     

     

     

    Get the next $BRSH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BRSH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BRSH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Bruush Oral Care Inc. (Amendment)

      SC 13D/A - Bruush Oral Care Inc. (0001913210) (Subject)

      2/23/24 5:15:27 PM ET
      $BRSH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Bruush Oral Care Inc. (Amendment)

      SC 13D/A - Bruush Oral Care Inc. (0001913210) (Subject)

      2/16/24 5:15:16 PM ET
      $BRSH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Bruush Oral Care Inc. (Amendment)

      SC 13G/A - Bruush Oral Care Inc. (0001913210) (Subject)

      2/14/24 2:43:40 PM ET
      $BRSH
      Medical/Dental Instruments
      Health Care

    $BRSH
    Leadership Updates

    Live Leadership Updates

    See more
    • Brüush Appoints New Chief Financial Officer

      VANCOUVER, BC / ACCESSWIRE / April 4, 2023 / Bruush Oral Care Inc. (NASDAQ:BRSH) ("Brüush" or the "Company"), a direct-to-consumer leader in the oral care category, has appointed Mandeek Manhas as the new Chief Financial Officer, the Company announced today.With an extensive background in finance and accounting, Mr. Manhas brings over 17 years of experience to this role.Prior to joining Brüush, Mr. Manhas held leadership positions in two reputable organizations, including a private real estate company with over $2.5 billion in asset value and a publicly listed, multi-national mining company with advanced development stage and exploration projects. Mr. Manhas has also spent eleven years in au

      4/4/23 8:45:00 AM ET
      $BRSH
      Medical/Dental Instruments
      Health Care
    • PARVIS INVEST INC. AND GRAVITAS II CAPITAL CORP. RECEIVE CONDITIONAL APPROVAL OF REVERSE TAKEOVER TRANSACTION AND FILE FILING STATEMENT

      VANCOUVER, BC, March 2, 2023 /CNW/ - Gravitas II Capital Corp. ("Gravitas II") (TSXV:GII) and Parvis Invest Inc. ("Parvis") are pleased to announce that, in connection with their previously announced proposed business combination (the "Transaction") as described in Gravitas II's news releases dated November 3, 2022 and August 29, 2022, the TSX Venture Exchange Inc. (the "Exchange") has conditionally approved the Transaction and the listing of the common shares of Gravitas II, following closing of the Transaction (the "Resulting Issuer"). The Transaction is expected to close on March 3, 2023, following which the common shares of the Resulting Issuer are expected to begin trading under the sym

      3/2/23 7:57:00 AM ET
      $BRSH
      $GOOGL
      Medical/Dental Instruments
      Health Care
      Computer Software: Programming Data Processing
      Technology
    • Brüush Appoints New Vice President of Sales & Business Development

      Mark Humphrey will focus on expanding Brüush's distribution footprint into new channelsVANCOUVER, BC / ACCESSWIRE / November 3, 2022 / Bruush Oral Care Inc. (NASDAQ:BRSH), a direct-to-consumer leader in the oral care category, has appointed Mark Humphrey to the key role of Vice President - Sales & Business Development, the company announced today. Mr. Humphrey will help Brüush drive sales growth, with a particular focus on expanding the brand's distribution footprint into new channels and evaluating strategic partnerships with other companies.Mr. Humphrey brings over 20 years of experience in leadership positions at high-growth organizations, where he primarily focused on revenue generation.

      11/3/22 9:30:00 AM ET
      $BRSH
      Medical/Dental Instruments
      Health Care

    $BRSH
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $BRSH
    SEC Filings

    See more
    • Brüush Receives Additional Delisting Notification to Address at Hearing

      VANCOUVER, BC / ACCESSWIRE / April 19, 2024 / Bruush Oral Care Inc. (NASDAQ:BRSH) (the "Company"), today announced that it received a notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq") on April 15, 2024 notifying the Company that because it is not compliant with Nasdaq's audit committee requirements as set forth in Listing Rule 5605 (the "Audit Committee Requirements"), this deficiency serves as an additional basis for delisting the Company's securities from Nasdaq. This deficiency will be considered by the Hearings Panel (the "Panel") at a hearing that has been scheduled for April 25, 2024 (the "Hearing") to address the Company's othe

      4/19/24 2:45:00 AM ET
      $BRSH
      Medical/Dental Instruments
      Health Care
    • Brüush Receives Additional Delisting Notification to Address at Hearing

      VANCOUVER, BC / ACCESSWIRE / March 25, 2024 / Bruush Oral Care Inc. (NASDAQ:BRSH) (the "Company"), today announced that it has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq") on March 20, 2024 notifying the Company that because the Company is delinquent in filing its annual report on Form 20-F for the year ended October 31, 2023, this deficiency serves as an additional basis for delisting the Company's securities from Nasdaq per Listing Rule 5810(d). This deficiency will be considered by the Hearings Panel (the "Panel") at a hearing that has been scheduled for April 25, 2024 to address the Company's other current deficiencies.As previou

      3/25/24 6:00:00 PM ET
      $BRSH
      Medical/Dental Instruments
      Health Care
    • Brüush Receives Nasdaq Delisting Notification and Files to Appeal

      VANCOUVER, BC / ACCESSWIRE / March 1, 2024 / Bruush Oral Care Inc. (NASDAQ:BRSH) (the "Company"), today announced that it has received a notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq") on February 27, 2024 notifying the Company of Nasdaq's determination to delist the Company's common shares from The Nasdaq Capital Market because the Company's common shares had a closing bid price of $0.10 or less for ten consecutive trading days as of February 26, 2024, which triggered a notice of delisting pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the "Low Priced Stocks Rule").In addition to the Low Priced Stocks Rule delisting notice, as

      3/1/24 11:20:00 PM ET
      $BRSH
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by Bruush Oral Care Inc.

      6-K - Bruush Oral Care Inc. (0001913210) (Filer)

      6/20/24 9:00:44 PM ET
      $BRSH
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by Bruush Oral Care Inc.

      6-K - Bruush Oral Care Inc. (0001913210) (Filer)

      4/18/24 5:25:04 PM ET
      $BRSH
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by Bruush Oral Care Inc.

      6-K - Bruush Oral Care Inc. (0001913210) (Filer)

      3/22/24 5:15:05 PM ET
      $BRSH
      Medical/Dental Instruments
      Health Care

    $BRSH
    Financials

    Live finance-specific insights

    See more
    • Arrive Acquires AirBox Technologies in Advance of Brüush Merger

      Acquisition Broadens Patent Portfolio and Propels Arrive's Smart Mailbox as a Service CapabilitiesVANCOUVER, BC and INDIANAPOLIS, IN / ACCESSWIRE / December 18, 2023 / Bruush Oral Care Inc. (NASDAQ:BRSH) ("Brüush") announced today that its pending merger partner, Arrive Technology Inc. ("Arrive"), a technology company focused on facilitating the last inch of the last-mile for autonomous delivery, has acquired AirBox Technologies ("AirBox"). This acquisition includes AirBox's patent portfolio, which Arrive believes will broaden the capabilities of its high-tech mailbox system designed for autonomous and conventional package delivery. In addition to acquiring the patent portfolio, AirBox's CEO

      12/18/23 7:00:00 AM ET
      $BRSH
      Medical/Dental Instruments
      Health Care